Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Pompe disease infantile-onset Indication Strategy Report 2026: GAA, Trials and Deals
30 July 2026
2026 Pompe disease infantile-onset indication strategy covering epidemiology, GAA biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Sialidosis Indication Strategy Report 2026: NEU1, Trials and Deals
30 July 2026
2026 Sialidosis indication strategy covering epidemiology, NEU1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Multiple sulfatase deficiency Indication Strategy Report 2026: SUMF1, Trials and Deals
30 July 2026
2026 Multiple sulfatase deficiency indication strategy covering epidemiology, SUMF1 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Megalencephalic leukoencephalopathy with subcortical cysts Indication Strategy Report 2026: MLC1, Trials and Deals
30 July 2026
2026 Megalencephalic leukoencephalopathy with subcortical cysts indication strategy covering epidemiology, MLC1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Mannosidosis Indication Strategy Report 2026: MAN2B1, Trials and Deals
30 July 2026
2026 Mannosidosis indication strategy covering epidemiology, MAN2B1 biology, active trials, transactions, unmet need, competition and market attractiveness.
Latest Hotspot
8 min read
Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation Indication Strategy Report 2026: DARS2, Trials and Deals
30 July 2026
2026 Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation indication strategy covering epidemiology, DARS2 biology, active…
Latest Hotspot
8 min read
Hypomyelination with atrophy of basal ganglia and cerebellum Indication Strategy Report 2026: TUBB4A, Trials and Deals
30 July 2026
2026 Hypomyelination with atrophy of basal ganglia and cerebellum indication strategy covering epidemiology, TUBB4A biology, active trials, transactions, unmet…
Latest Hotspot
8 min read
Arginine:glycine amidinotransferase deficiency Indication Strategy Report 2026: GATM, Trials and Deals
30 July 2026
2026 Arginine:glycine amidinotransferase deficiency indication strategy covering epidemiology, GATM biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia Indication Strategy Report 2026: CSF1R, Trials and Deals
30 July 2026
2026 Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia indication strategy covering epidemiology, CSF1R biology, active trials,…
Latest Hotspot
8 min read
POLR3-related leukodystrophy Indication Strategy Report 2026: POLR3A, Trials and Deals
30 July 2026
2026 POLR3-related leukodystrophy indication strategy covering epidemiology, POLR3A biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Glucose transporter type 1 deficiency syndrome Indication Strategy Report 2026: SLC2A1, Trials and Deals
30 July 2026
2026 Glucose transporter type 1 deficiency syndrome indication strategy covering epidemiology, SLC2A1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Cerebral folate deficiency Indication Strategy Report 2026: FOLR1, Trials and Deals
30 July 2026
2026 Cerebral folate deficiency indication strategy covering epidemiology, FOLR1 biology, active trials, transactions, unmet need, competition and market…